Mati Therapeutics Inc.   Report issue

For profit Phase 2
Founded: Austin TX United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2012
NCT00650702
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Mati Therapeutics | Mati Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

latanoprost (xalatan) (11 trials)

nepafenac (nevanac) (1 trial)

olopatadine (patanol) (1 trial)

timolol (blocadren) (6 trials)

Drugs in Other Trials (1)

travoprost (travatan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 2)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Hypertension (Phase 2)

Inflammation (Phase 2)

Ocular Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 5